ChemoCentryx, Inc. (CCXI)

Oncology Corporate Profile

Stock Performance

2.4000
-0.0700

HQ Location

850 Maude Avenue
Mountain View, CA 94043

Company Description

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer.

Website: http://www.chemocentryx.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
CCX872CCR2 inhibitorPancreatic cancerII
CXCR2PD-L1 inhibitorVarious cancer typesPreclinical
CCR5PD-L1 inhibitorVarious cancer typesPreclinical
CCR2PD-L1 inhibitorVarious cancer typesPreclinical
CCR1PD-L1 inhibitorVarious cancer typesPreclinical

View additional information on product candidates here »

Source: http://www.chemocentryx.com

Recent News Headlines

5/22/2017 12:17 pm

5/22/2017 12:17 pm

5/22/2017 12:17 pm

5/22/2017 12:17 pm

5/16/2017 06:17 am

5/15/2017 12:17 pm

5/15/2017 12:17 pm

5/15/2017 12:17 pm

5/12/2017 06:17 am

5/12/2017 06:17 am

5/12/2017 06:17 am

5/12/2017 06:17 am

5/11/2017 06:17 pm

5/11/2017 06:17 pm

5/11/2017 06:17 pm

5/11/2017 06:17 pm

5/10/2017 12:17 pm

5/10/2017 12:17 pm

4/27/2017 06:17 am

4/9/2017 06:17 am

ChemoCentryx Receives FDA Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy (C3G)

3/22/2017 12:03 pm

[GlobeNewswire] - MOUNTAIN VIEW, Calif., March 22, 2017-- ChemoCentryx, Inc.,, a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, announced today that the ...